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1. INTRODUCTION 
 2 
1.1 PROSTATE CANCER 
1.1.1 EPIDEMIOLOGY AND ETIOLOGY 
 
 Prostate cancer (PC), is the most common malignancy in males with an incidence of 
2141 cases in 2015 in Croatia and is the third most common cause of death (1). Changes in 
the prostate increase with age with an increased incidence of PC in the population older than 
70 years. It occurs more often in the African-American male population than in white men 
(2). There is a familial factor in the development of cancer with a two times increased risk if 
one first-degree relative is affected and a four times increased risk if two or more relatives are 
affected (2).A BRCA2 mutation leads to a fivefold increased risk of PC (2). Additionally, 
there is a chance of being affected by PC as well as benign prostatic hyperplasia (BPH). The 
risk of developing PC is 1 in 10.000 for men younger than forty, 1 in 103 for men 40-59 years 
of age and 1 in 8 for men between 60 and 79 years (3). PC presents with 83 new cases each 
year and leads to 9 confirmed deaths per year, leading to a mortality/incidence ratio of 0.38 
(1). 
 
1.1.2 PATHOLOGY   
 
 The vast majority of PC are adenocarcinomas. The remaining part can be subdivided 
into epithelial and non-epithelial tumors with sarcomas, small cell carcinomas, neuroendo-
crine tumors and transitional cell tumors being the most common. The long-term use of an-
drogen deprivation therapy can lead to the development of neuroendocrine tumors (4).  
 On cytology, PC is cytologically characterized by hyperchromatic, enlarged nuclei 
with prominent nucleoli, mitotic figures, and amphophilic cytoplasm (5). The cytoplasm is 
usually abundant. Architectural features include small glands which infiltrate between benign 
surrounding glands, and regions with an increased number of glands which is not inflamed 
which can be cancer (5). An additional factor to differentiate PC from a normal gland or be-
nign prostatic hyperplasia is that in cancer the basal cell layer is missing. Prostate intraepithe-
lial neoplasia (PIN) and atypical small acinar proliferation (ASAP) are now considered to be 
premalignant states with PIN having a strong association with PC on biopsies (6). Intraductal 
dysplasia is considered as a precursor to PC because the frequency of PCs is high in prostate 
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glands with multiple locations of dysplasia (7). Staining for acid phosphatase and prostate-
specific antigen is characteristic for a PC (3). 
 Most of the high-grade prostatic intraepithelial neoplasia develop in the peripheral 
zone of the prostate gland, being the most common location for PC (5). 10-20% develop in 
the transition zone and 5-10% in the central zone (3). Around 85% of these tumors are multi-
focal. Cancers involving the central zone of the prostate gland are highly malignant and have 
a different route of spread compared to PC in other zones (8). Furthermore, androgen and 
progesterone receptors have been found on the surface of PC cells (9). 
 
1.1.3 NATURAL HISTORY OF DISEASE 
 
 PC invades locally into the gland and then through the prostatic capsule into the sur-
rounding structures. Invasion can include the seminal vesicles which leads to a higher likeli-
hood of local recurrence or distant disease. If the tumor invades the bladder trigone, symp-
toms of ureteral obstruction will develop. Rectal invasion is possible but rare due to the 
Denonvilliers' fascia. Lymph node metastases are more common in advanced stages and af-
fect the obturator, external iliac, and internal lymph node chains. PC usually spreads to distant 
sites via retrograde venous spread through the vertebral plexus. The axial skeleton, especially 
the lumbar spine is most commonly affected. The resulting bone lesions are osteoblastic and 
can result in pathologic fractures. If the metastases involve the vertebral body, this can lead to 
spinal cord compression. Lung, liver, adrenal glands are the most common affected internal 
organs (2,9). 
 
1.1.4 CLINICAL FINDINGS 
 
 Usually, PC is asymptomatic. If symptoms are present, these often suggest local infil-
tration or metastatic spread of the disease. Symptoms caused by prostatic outflow obstruction 
are hesitancy, frequency, poor stream and nocturia (3). Haematospermia and erectile dysfunc-
tion are possible. These symptoms can also be caused by benign prostatic hyperplasia. Meta-
static disease affecting the bones will cause bone pain or spinal cord compression and hyper-
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calcemia. General symptoms related to malignancy are possible which include malaise, ano-
rexia and weight loss (2). 
 
1.1.5 SCREENING AND DIAGNOSIS 
 
 Digital rectal examination (DRE) and prostate-specific antigen (PSA) levels are the 
basic tests for detecting PC. DRE is focusing on the size, consistency and abnormalities of the 
gland and surrounding tissues but it should not be used alone (10). The majority of these can-
cers appear in the peripheral part of the prostate gland and can be detected on DRE. On DRE, 
the cancer may be palpable through the rectum as a hard nodule or a diffusely infiltrating ir-
regularity. A loss of the midline sulcus of the prostate gland is typical. Overall 20-25% of 
patients with positive DRE have cancer (2). Combining PSA measurement with DRE and 
ultrasound (US) show better results than rectal examination alone (11). 
 Today the most important test for the diagnosis of PC is the PSA test. This test is very 
sensitive for the prostate but relatively non-specific for PC because other non-malignant states 
can also increase the PSA levels in the blood (3). 
 Trans rectal ultrasound (TRUS) is used to guide trans rectal biopsies and other diag-
nostic procedures and to evaluate the primary tumor for further staging. Abnormal findings on 
TRUS are not necessary related to malignancy. It is important to describe the dimension of 
the prostate gland, volume, shape, symmetries, echogenicity and the involvement of surround-
ing tissues including the seminal vesicles and ampullas of the duct deferens (12). 
 If there is suspicion of PC due to abnormal findings in DRE and PSA values, a pros-
tate biopsy is the next step to confirm the diagnosis. Under TRUS guidance, biopsies are tak-
en from the peripheral part of the gland, with the possibility of including other suspicious are-
as as well. An extended 12-core biopsy is advised. The procedure is carried out under local 
anesthesia with antibiotic prophylaxis before the procedure. Indications for a TRUS guided 
biopsy are a PSA level ³ 4 ng/ml on the first consultation, suspicious finding on DRE, and a 
suspicious rise in PSA (10). If the biopsy is negative but the PSA is abnormal, men should 
undergo repeated biopsy (2). A prostate biopsy can lead to haematospermia, rectal bleeding, 
fever above 38,5 °C (10). If systematic biopsy is compared with ultrasound-guided biopsy, 
the guided biopsy shows better diagnostic performance, meaning better sensitivity, specifici-
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ty, and negative/positive predictive values (13). Colour Doppler and contrast-enhanced target-
ed biopsy show the highest sensitivity and specificity (13).  
 Magnetic resonance imaging (MRI) examines the prostate gland and the surrounding 
tissues such as rectum and bladder with better results with regard to cancer in the prostate and 
local extend (2). Specific rectal coils which are placed immediately adjacent to the prostate 
gland are used to detect PC (14). The use of multiparametric MRI (mpMRI) is able to detect 
PC in patients who did not have a biopsy before or in case the biopsy was negative and in 
addition to that a significant disease can be ruled out (15). MpMRI consists of a T2-weighted 
(T2w) sequence, a diffusion-weighted sequence (DWI), and a dynamic contrast-enhanced 
(DCE) evaluation (16). 
 In case of an increased PSA and positive DRE but there is a negative histologic find-
ing on biopsy, the multiparametric MRI can be used to specify the location of the tumor. The 
result is more accurate with a TRUS-biopsy. In addition to that, an MRI guided biopsy is also 
possible. 
 T1-weighted (T1w) images show a high signal in adjacent lymph nodes and bone mar-
row. These pictures are not useful for PC detection because the normal gland appears hy-
pointense and different zones of the prostate gland can´t be differentiated (10). An important 
benefit of the T1w image, is to detect post biopsy hemorrhage which is seen with a high in-
tensity signal (17,18). If the hemorrhage exclusion sign on a T1w image is combined with a 
related homogenous low-signal intensity area on a T2w image, that is strongly predictive of 
PC (19). 
 The structure of the prostate gland and seminal vesicle is studied on a T2-weighted 
image. The normal peripheral zone of the prostate glands appears hyper intense on a T2 se-
quence due to the high amount of gland tissue (10). An important landmark for staging is the 
prostatic capsule which presents as a thin hypointense line (16). Due to the flexible amount of 
stromal and glandular tissue in the transitional zone, it appears heterogeneous (10). PC on a 
T2w picture has a low T2w signal due to the increased cell density which leads to a decreased 
water content (2). The differential diagnosis includes focal fibrosis or a stromal BPH node. 
The cell density is proportional to the aggressiveness of the tumor. The extracapsular exten-
sion can be visualized on a T2 sequence and presents with asymmetry or macroscopic inva-
sion of the neurovascular bundle, retraction of the capsule, irregularity of the prostatic con-
tour, change in the recto-prostatic angle, and signs for a rupture of the capsule with extension 
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into the periprostatic fat (16). The limitations of the T2w sequence is, that PC cannot be ex-
cluded when the lesion is less than 10 mm and < 0.3cm (20). Lesion larger than 20 mm have a 
detection rate of 89% (20). 
 DWI shows the movement of matter in space until a homogenous distribution and is 
therefore capable of measuring diffusion restrictions (10). It correlates with the Gleason score 
(GS) and the cellularity (16). The diffusion limitation is measured with the apparent diffusion 
coefficient (ADC) and the b-value describes the degree of diffusion weighting which enable 
the quantification of a diffusion map (10). B-values above 1000 is important for measuring 
the cellularity and therefore cell density which is specific value for the aggressiveness of PC 
(21). An area of low diffusion appears hypointense on an ADC map due to a low diffusion 
coefficient or low ADC values (16). This method does not require contrast media. Normal 
prostatic tissue is visible as an area with high ADC values. The ADC value shows the best 
correlation to the GS and the aggressiveness of the PC (22). DWI images can differentiate 
between a normal central zone, the peripheral zone, a prostatic cyst, BPH nodule and PC (23). 
The advantages of this technique are a short imaging time, no need for contrast media and 
relatively simple post-processing requirements (24). 
 DCE is a functional MRI image that shows a relationship to angiogenesis (16). This 
method uses low molecular weight gadolinium contrast media (10). As a result of the in-
creased vascularity of the PC, DCE pictures show an intense and early contrast media wash-in 
that is followed by an intense and early wash-out (16). The normal tissue in the peripheral 
zone shows a slower and more progressive wash-in (16). Therefore, DCE enables the exami-
nation of the micro vascularization and neoangiogenesis of PC (10). Namimoto et al. found 
out, that the combination of DCE and postcontrast T1 sequences is 82% accurate which led to 
the conclusion that dynamic pictures are helpful in the evaluation of low intensity lesions in 
the peripheral zone (25). Endorectal dynamic imaging increased the diagnostic sensitivity 
from 77.8 to 88.9% in localized PC (26). In addition to that DCE together with an endorectal 
surface coil results in a more accurate determination of the tumor localization, penetration of 
the capsule, invasion of seminal vesicle, and involvement of the neurovascular bundle (27). In 
sum, DCE increases the specificity and sensitivity of detecting especially PC in peripheral and 
anterior zones and therefore decreases the rate of false-positive results (10). 
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 The examination protocol of the prostate gland MRI should include high resolution 
T2-sequences in axial, coronal and sagittal planes together with an axial T1 image of the pel-
vis and diffusion and perfusion (T2 + DWI + DCE) imaging of the prostate (10). 
 CT-scan gives a better and more detailed view of the lymph node changes in the 
common iliac and para-aortic regions. It is used when MRI scans are contra-indicated because 
it has inferior sensitivity and specificity for detection of extra prostatic involvement. 
  18F-Fluoride PET/CT is useful for the detection of metastases in patients with 
high risk prostate cancer. With this technique patients who have metastases can be separated 
from those who do not have metastases and there can be treated with curative local radiother-
apy or surgery (28). 
 
1.1.6 UCSF CANCER OF PROSTATE RISK ASSESSMENT (CAPRA) SCORE 
 
 The score is used to predict the recurrence risk of PC after radical prostatectomy. In 
order to calculate the CAPRA score, points are given for the GS, PSA level, T-stage, % of 
positive biopsy cores, and age getting a range from 0-10 points (3). If the score increases by 2 
points that means a doubling of the risk. The disease is divided into three groups: 0-2 indicate 
a relatively low risk, 3-5 are intermediate, and 6-10 are high risk (3). In addition to that the 
CAPRA score can be used for prediction of development of metastases, prostate cancer-
specific mortality, and all-cause mortality with good accuracy (29). On top of that the bio-
chemical-recurrence-free survival at 3 years can be correctly predicted (30). Summarized, the 
CAPRA score primarily indicates the relative risk and helps in predicting the outcome after 
radical prostatectomy. 
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1.1.7 PSA 
 
 The PSA is a kallikrein-related serine protease with the effect of liquefying the semi-
nal coagulum. It is produced by non-malignant and malignant epithelial cells. Therefore, the 
antigen is prostate-specific, not prostate cancer specific and can be used in screening as well 
as in risk stratification (3). In serum PSA exists complexed with a protease inhibitor or un-
complexed (free) form. The free form is rapidly eliminated from the blood via the kidneys and 
has a half-life of 12-18h (2). Prostatitis and BPH can increase the PSA levels in serum. Serum 
PSA levels are not significantly affected by DRE but a prostate biopsy can increase the levels 
up to tenfold (9). PSA levels should not be detectable after removal of the prostate gland for 
about 6 weeks. A normal PSA value is defined as ≤4 ng/ml and a positive predictive value for 
a value between 4 and 10 ng/ml is approximately 20-30% (3). According to a PC prevention 
trail there is no PSA level below which the risk of PC falls to zero. There is rather a continu-
um of risk (31). In addition to that, prevalence of biopsy detected prostate cancer in patients 
with a PSA level in normal range is not rare (32). 
 PSA velocity is related to the rate of change of serum PSA. The PSA doubling time 
points to the required time needed to double the amount of PSA. Patients with an increase in 
PSA levels by 0.75 ng/ml appear to be at an increased risk of developing cancer (3). To pre-
vent misinterpretation the PSA levels should be taken by the same laboratory over a period of 
18 months. 
 The PSA levels are elevated on average approximately 0.12 ng/ml per gram of BPH 
tissue and increases with age. In conditions like prostatitis and BPH, the levels are increased 
as well. The PSA density describes the ratio of PSA to prostate gland volume. 
 PSA doubling time (DT) is the time needed for the PSA level to double. It reflects the 
tumor growth and is especially important after prostatectomy. PSA DT is not used for diag-
nostics but for deciding which therapy to use and for the control of the therapy (10). The drug 
finasteride decreases the rate at which the tumor secretes PSA into the blood (33). A PSA DT 
of less than 3 months is related to a preoperative PSA velocity of < 2.0 ng/ml/yr, and a GS 7 
or 8-10, which leads to a shorter survival caused by an increased prostate cancer-specific mor-
tality (PCSM) (34). 
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 PSA failure is the rise in PSA levels in PC patients after surgery or radiation. A rise of >0.2 ng/ml after surgery is considered failure. If there a level of >2 ng/ml above the nadir 
after radiation therapy, that is considered failure (35). 
 
1.1.8 GLEASON SCORE (GS) 
 
 After taking a biopsy or radical prostatectomy, the tissue is examined under the micro-
scope according to the growth pattern and scored in the GS. It scores the dominant and the 
secondary dominant pattern from 1 (well differentiated) to 5 (undifferentiated). The sum gives 
a total score of 2-10 points, with a score above 8 having a poor outcome. In addition to the 
invasion of perineural tissue and spread to extracapsular tissues as seminal vesicles, rectum 
and bladder. A GS of 3 resembles a low-grade disease, score of 4 resembles an intermediate-
grade disease and a score of 5 resembles a high-grade disease. (3) The most important part in 
the Gleason score system is the primary score of the tumor because it determines the biologic 
risk. Epstein et al. introduced a new classification according to five grade groups in which 
group 1 has a GS £6; group 2 has GS 7 (3+4); group 3 – GS 7 (4+3); group 4 – GS 8 and 
group 5 – GS 9-10 (36). 
 
1.1.9 STAGING AND RISK STRATIFICATION 
 
 PC is staged according to the tumor, node, metastasis (TNM) staging system (table 1). 
Included are stages which can be identified by an abnormal PSA (T1c), which are clinically 
confined to the gland but are palpable (T2) and tumors which involve adjacent or distant 
structures (T3 and T4) (2). In the Tx stage the primary tumor cannot be assessed and in T0 
there is no evidence of a primary tumor. 
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Table 1: TNM staging of PC 
Localized disease 
 
 T1 clinically inapparent tumor, neither palpable nor visible by imaging 
 T1a Tumor incidental histologic finding in >5% of resected tissue; not palpable 
 T1b tumor incidental histologic finding in >5% of resected tissue 
 T1c tumor identified by needle biopsy (e.g., because of elevated PSA) 
 T2 tumor confined within prostate 
 T2a tumor involves half of the lobe or less 
 T2b tumor involves more than one half of one lobe, not both lobes 
 T2c tumor involves both lobes 
 
   
Local ex-
tension 
  T3 tumor extends through prostatic capsule 
 T3a extracapsular extension (unilateral or bilateral) 
 T3b tumor invades seminal vesicle(s) 
 T4 tumor is fixed or invades adjacent structures (rectum, bladder, levator muscles, external sphincter, and/or pelvic wall 
   Metastatic disease 
 N1 positive regional lymph nodes 
 M1 distant metastasis 
 
   Revised from SB Edge et al (eds): AJCC Cancer Staging Manual 
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 PSA-level, GS and the T-stage with or without extend of the involvement of the biop-
sy care are important to assess the risk of cancer spread. The American Urology Association 
(AUA) guidelines assign men into three categories. The low-risk group constitutes a PSA ≤10 
ng/ml, Gleason ≤6, and a clinical stage T1 or T2a. In the intermediate group are men with a 
PSA 10-20 ng/ml, Gleason score 7, or clinical T2b. High risk men have a PSA >20 ng/ml, 
Gleason score 8-10, or clinical stage T2c or T3a. (3) Problems with this system occur due to 
the missing differentiation between Gleason scores 3+4 or 4+3, which are different in terms 
of biologic risks. 
 If the stage is <T2a,	Gleason	score	≤6	and	the	PSA	≤10	ng/ml	the	risk	of	metastatic	spread	is	low (37).	
 Patients with a pre-treatment PSA velocity of 2 ng/ml/year, an interval to PSA failure 
of <3 years and a post-treatment doubling time <3 months have an increased risk of metastatic 
spread and prostate cancer-specific mortality and are not suitable for salvage therapy (38). 
 
1.1.10 TREATMENT 
 
 The therapy given to the patient depends on the stage of the tumor, age, symptoms, 
and condition of the patient, the capability of the therapy to provide disease -free survival. 
 
1.1.10.1 LOCALIZED DISEASE 
 
 Local prostate cancer is stage T1-T2c without metastases and lymph node involve-
ment. Therapy options are watchful waiting and active surveillance, radical prostatectomy, 
radiation therapy and cryotherapy (3). 
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1.1.10.1.1 ACTIVE SURVEILLANCE 
 
 In active surveillance, men are followed with DRE, PSA tests, and prostate biopsies in 
fixed intervals to assess the progression of PC. This method is suitable for patients with PSA ≤10 ng/ml, tumor stage T1-T2a, Gleason score ≤6 (39). Treatment is introduced with the first 
sign of progression (3). 
 
1.1.10.1.2 RADICAL PROSTATECTOMY 
 
 The aim of a radical prostatectomy (RP) is to remove the cancer completely with a 
clear margin, conserve continence by maintaining the external sphincter, and to preserve po-
tency by sparing the nerves in the neurovascular bundle (2). This method is advised for pa-
tients with a life expectancy of more than 10 years because it showed improved survival com-
pared to active survival (40). In case of a low-risk disease, an open or robotic radical prosta-
tectomy can be performed in which the postoperative erectile dysfunction is preserved by 
unilateral or bilateral cavernous nerve sparing. For the high-risk group, a non-nerve-sparing 
surgery is performed (41). In use are the retropubic, perineal, or robotic laparoscopic ap-
proach. In the open radical retropubic approach, the peritoneum is not opened but the lymph 
nodes are removed between the bilateral obturator vessels and the external iliac vein (41). The 
approach determines the possible complications of surgery. In the retropubic approach, urine 
leaks, lymphocele and urinary or rectal damage are possible. Iatrogenic ileus is a possible 
complication of the robotic assisted approach. For all RPs, there is a risk of urinary inconti-
nence and erectile dysfunction. The erectile dysfunction usually comes back after about 6 
months after surgery and a better recovery is related to younger age, quality of sexual function 
before operation and a good surgical technique (2). 
 After surgery, the PSA level should be <0.2 ng/ml within 6 weeks of surgery (3). If the 
levels rise above 0.2 ng/ml, PSA failure is present (42). In case of positive lymph node in-
volvement, adjuvant androgen deprivation therapy should be offered (3). High risk patients 
with a pT3 PC or when the surgical margins were positive after RP, can be additionally treat-
ed with immediate external beam radiation to improve the progression-free survival and local 
control of the disease (43). 
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1.1.10.1.3 RADIATION THERAPY 
 
 The radiation therapy (RT) can be delivered via external beam therapy or by brachy-
therapy in which a radioactive source is placed close to the tumor. 
 Before external beam RT it is important to make three-dimensional treatment plans in 
order to increase the dose of radiation delivered to the prostate gland and to decrease in-
volvement of the surrounding tissues. This technique allows safe delivery of 65 to 70 Gy to 
the prostate gland. With the help of newer treating plans like three-dimensional, conformal 
radiation therapy (3DCRT) and intensity-modulated radiation therapy (IMRT) it is possible to 
target the prostate gland more precisely which leads to a decrease in acute and late toxicities 
(3). In addition to that, the delivery of higher doses >80 Gy are possible which leads to a bet-
ter biochemical outcome after treatment. The results of RT can be improved by neoadjuvant, 
concurrent, and adjuvant androgen deprivation therapy (ADT). A decline in PSA to <0.5 or 1 
ng/ml, steady PSA levels, and a negative prostate biopsy after 2 years define cancer control 
(2). Biochemical failure is defined a rise in PSA by >2 ng/ml above the nadir (Phoenix defini-
tion) (44). Most of the side-effects of RT are limited in extend but radiation is associated with 
a higher frequency of bowel complications like diarrhea and proctitis. Other side-effects are 
urinary urgency, frequency, hematuria, rectal bleeding and tenesmus. Posttreatment erectile 
dysfunction as after surgery is as well possible after radiation therapy but it is due to a disrup-
tion of the vascular supply not due to nerve damage. Higher doses lead to an incidence of rec-
tal toxicity and doses ≥73 Gy increase the late urinary toxicities (45). If external beam RT is 
combined with ADT, there is a transient loss of sexual function which improves within 9 
months postoperatively (46). Combining external beam RT with brachytherapy leads to a 
worsening of urinary function (46). In order to decrease the size of the prostate and therefore 
a decreased involvement of the surrounding tissues, to increase the local control rates, and to 
decrease the systemic failure, neoadjuvant ADT can be given to the patient (2). Monotherapy 
with gonadotropin-releasing hormone (GnRH) agonists, in addition to RT showed increased 
survival and disease-free survival benefits in patients with increased risk of metastatic spread 
(47). According to Crook et al. there is no significant difference whether to use intermittent or 
continuous ADT in patients after radiotherapy (48). 
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 Brachytherapy includes the direct implementation of a radioactive source into the 
prostate. These implants can be permanent with iodine 125 or palladium 103 having a lower 
dose rate but an overall higher total dose delivered in comparison to temporal implants (3). 
The therapy is based on the fact that the dose of radiation decreases with the square distance 
from the source. Brachytherapy is usually well tolerated but many patients experience urinary 
frequency and urgency. 
 
1.1.10.2 METASTATIC DISEASE 
  
 Death due to PC is often a result of the failure of controlling the metastatic spread. PC 
is in most cases hormone dependent, especially to testosterone. Testosterone is the most im-
portant circulating androgen and is secreted in the testis by Leydig cells (3). Prostate cells 
take up this androgen and convert it to dihydrotestosterone (DHT), which is the key intracel-
lular androgen. Interrupting this is the main focus in treatment of metastatic PC (2,3). 
 For symptomatic M1 patients it is recommended to perform an immediate castration to 
prevent the development of a further progression of the disease and palliation of symptoms 
(49). Asymptomatic M1 patients, the immediate castration should be offered to prevent the 
progression of PC (49). 
 
1.1.10.2.1 NONCASTRATE METASTATIC PC 
 
 Metastatic hormone sensitive PC can be treated with ADT and early administration of 
docetaxel which shows increased survival rates but increases adverse events as well (50). In 
addition to that, abiraterone acetate and prednisolone can be added to ADT in order to im-
prove the development of pain, PC symptoms and the quality of life (51). 
 Patients with a testosterone levels >150 ng/dL and visible metastases on imaging stud-
ies are in the state of noncastrate metastatic PC and present with pain due to osseous spread 
and less commonly spinal cord compression, coagulopathy or bone marrow compression (2). 
 15 
 The main focus of treating metastatic PC is to deplete or lower the androgen produc-
tion and/or block the binding of these hormones (2). This can be achieved by testosterone 
lowering agents, antiandrogens, androgen deprivation therapy (ADT) or surgical treatment. 
 Androgen depletion is not a curative therapy because some cells are already castration 
resistant when PC presents for the first time. For that reason, the PSA level in 60-70% of pa-
tients will return to normal values, there is a regression of detectable lesions in about 50% (2). 
 Surgical orchiectomy is used to remove the testis and stop the production of testos-
terone (2). This technique was the “gold standard” but nowadays replaced by chemical castra-
tion (52). 
 
1.10.2.2 TESTOSTERONE LOWERING AGENTS 
 
 Gonadotropin-releasing hormone (GnRH) agonists and antagonists induce androgen 
deprivation by blocking the luteinizing hormone (LH) on the pituitary level (3). Goserelin 
acetate, triptorelin pamoate, histrelin acetate and leuprolide acetate are approved for the 
treatment of PC (3). After administration of GnRH agonists, the LH and follicle-stimulating 
hormone levels rise initially and cause the “flare phenomenon” due to the rise in the testos-
terone level, which leads to bone pain, cord compression and bladder outlet obstruction (53). 
After this initial reaction a downregulation of receptors takes place which leads to a chemical 
castration (2). 
 GnRH antagonists like degarelix on the other hand, don´t cause the initial rise in tes-
tosterone levels and can achieve a chemical castration within 48h (2). Compared to GnRH 
agonists, the antagonists show a more rapid suppression of LH, RH and testosterone in addi-
tion to a better disease control with less side-effects (54). 
 In patients with impending spinal cord compression, bilateral orchiectomy or LHRH 
antagonist should be considered as first-line treatment (49). 
 Administration of testosterone lowering agents can lead to the androgen depletion 
syndrome which is characterized by fatigue, weakness, hot flushes, impotence, loss of libido, 
anemia, sarcopenia (2). Other side effects are a decrease in bone density and an increased risk 
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of diabetes and cardiovascular disease (55). By prescribing calcium, vitamin D supplements 
or in severe cases bisphosphonates, the bone changes can be prevented (3). 
 
1.10.2.3 ANTIANDROGENS 
 
 Drugs like flutamide, bicalutamide, and nilutamide, block the androgen receptors in 
the prostate cell and therefore block the flare disease if they are given together with GnRH 
agonists (2). Non-steroidal antiandrogens should not be used as mono therapy due to the lack-
ing benefits (2,49). In M1 patients with advanced metastatic disease, it is recommended to 
perform short-term administration of antiandrogens due their suppressive effect on the “flare 
phenomenon” (49). 
 
1.10.2.4 INTERMITTENT ANDROGEN DEPRIVATION THERAPY (IADT) 
 
 IADT uses the “on- and-off” approach to decrease side effects and to prevent the pros-
tate cells from becoming resistant to ADT (2). The intermittent deprivation seems to be as 
effective as the continuous use but shows tolerability and quality of life advantages (56). 
There is evidence that using IADT can be helpful for patients with relapsing, locally ad-
vanced, or metastatic PC with a good initial response to androgen deprivation (57).  
 
1.1.10.3 CASTRATION RESISTANT METASTATIC PROSTATE CANCER (CRPC) 
 
 CRPC is defined as a progressing disease despite androgen suppression by surgical 
medical intervention, where the testosterone level was <50 ng/ml (2). Furthermore, a bio-
chemical progression includes three following increases of the PSA level above the nadir with 
>2 ng/ml which are 1 week apart (49). In addition to biochemical progression, radiological 
progression includes the presence of two or more bone lesions on a bone scan or a progression 
of a soft tissue lesion (49). Transdifferentiation or androgen receptor (AR) independence, 
leads to the development of CRPC (58). The result is an increase in the PSA level which indi-
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cates signaling through AR signaling axis despite androgen deprivation therapy (2). The 
prognosis of patients with CRPC is poor and needs multidisciplinary approach (59). The base-
line PSA and PSA velocity independently predict the survival and development of bone me-
tastases (60). 
 Docetaxel belongs to the taxane-based chemotherapeutics. In combination with pred-
nisone it approved for the treatment of CRPC (59). In high risk patients with metastatic CRPC 
characterized by a PSA >114 ng/ml, visceral metastases, <12 months response to ADT and 
tumor related complications, first-line chemotherapy is indicated (61). 
 Cabacitaxel is a non-cross resistant taxane which can be offered to patients who pro-
gressed after docetaxel therapy (62). After docetaxel failure, it shows a better overall survival 
compared to mitoxantrone with prednisolone (61). 
 Sipuleucel-T is a biological agent based on autologous dendritic cells which are capa-
ble of detecting prostatic acid phosphatase (3). It may be offered to asymptomatic or minimal-
ly symptomatic patients (62). 
 Abiraterone acetate is a CYP17 inhibitor which leads to a decreased production of 
androgens in the PC, testis and adrenal glands (2). Its use shows increased radiographic pro-
gression-free survival and possible improved overall survival in patients with CRPC who did 
not receive chemotherapy (63). Possible side-effects are due to the long-term use of cortico-
steroids like inducing a loss of bone minerals and inducing osteoporosis, diabetes and central 
nervous system effects. On top of these effects, abiraterone acetate can lead to an increase in 
blood pressure, increased level of fatty acids in the blood, anemia and urinary tract infections. 
 Enzalutamide is a new generation nonsteroidal antiandrogen which has a higher affini-
ty for the AR receptors and distinctively blocks nuclear location and DNA binding of the re-
ceptor complex (2). This drug improves the patient related outcomes and delays the develop-
ment of the first skeletal metastases (64). Enzalutamide similarly prolongs survival if given 
after chemotherapy (65). The most common side effects are fatigue and hypertension (49). 
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1.10.4 BONE METASTASES 
 
 Painful bone metastases are a characteristic feature of CRPC. Therapy with short or 
long-course external beam RT is effective in treating bone lesions (66). 
 Alpharadin is alpha-emitting radium-223 chloride, which finds the metastatic bone 
lesions (2). 
 Bisphosphonates like zoledronic acid are used to block bone resorption mediated by 
osteoclasts. 
 Denosumab is a RANK ligand inhibitor protecting against bone loss due to androgens 
(2). The human monoclonal antibody targets RANKL which is an important mediator of oste-
oclast activity and survival (49). 
 
1.1.11 FOLLOW-UP 
 
 Follow-Up is performed by using DRE and PSA-level examinations together with 
history taking specific for the disease (49). 
 After RP, PSA should be unobserved within 6 weeks after successful treatment. If the 
levels continue to be elevated, that can be due to residual cancer tissue. A rapid increase in 
PSA can point to distant metastases (49). The post RP PSA levels usually precede a disease 
progression but in some cases the disease can progress without a PSA change (67). 
 
 After RT, the PSA level drops slowly which can last up to 3 years or more. Failure is 
defined a PSA >2 ng/ml above the nadir (49). PSA doubling times (DT) seems to correlate 
with the location of recurrence, meaning local recurrence has a longer DT than distant recur-
rence (68). 
 During ADT the PSA level helps to follow the course of the PC and predict the sur-
vival (49). Patients with a PSA of <0.2 ng/ml have a median survival of 75 months, PSA 0.2-
0.4 ng/ml or less have 44 months and PSA >0.4 ng/ml have 13 months (69). 
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1.2 SALVAGE RADIOTHERAPY 
 
1.2.1 DEFINITION 
 
 Salvage radiotherapy (SRT) is a method which uses radiation to control the recurrence 
(local or biochemical) of PC after RP and to avoid or delay the development of metastases 
which can lead to the death (70). It delivers radiation to the prostate bed and possibly to the 
surrounding tissues like lymph nodes (71). The outcomes after SRT are reported as biochemi-
cal recurrence, biochemical recurrence-free survival (bRFS), local recurrence, local recur-
rence-free survival, metastatic recurrence, metastatic recurrence-free survival (mRFS), clini-
cal progression-free survival, cancer-specific survival, and overall survival (71). 
 
1.2.2 INDICATION 
 
 SRT is indicated only for patients with PSA (biochemical) or local recurrence after 
RP, in whom distant metastases are not present (71). A PSA level > 0.2 ng/ml after RP is con-
sidered biochemical failure (42). Adverse pathologic findings at RP such as the invasion of 
the seminal vesicles, positive surgical margins, or extraprostatic invasion should be treated 
with adjuvant radiotherapy (71). Characteristics of the PC at time of diagnosis, PSA doubling 
time (PSADT) which follows the relapse, and the PSA level when the patient entered the pro-
tocol seem to be associated with progression to development of metastatic PC (72). A retro-
spective study found out that patients with a high-grade PC and/or a fast PSADT who natural-
ly would progress to metastatic PC can profit from SRT treatment (73). 
Postoperative radiation may not be necessary in men who have a preoperative PSA velocity of 
0.5 ng/ml/yr or less, PSA level which is < 10 ng/ml, a nonpalpable PC with a GS <6 when 
diagnosed (74). 
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1.2.3 DIAGNOSTICS 
 
 Clinical history, physical examination, and the PSA kinetics are the main tests in eval-
uating PC recurrence after RP (75). 
 
1.2.4 RISK OF POST TREATMENT COMPLICATIONS 
 
 SRT causes toxic effects mostly in the genitourinary (GU) and gastrointestinal (GI) 
system but can as well lead to secondary pelvic malignancies (70). Low doses as well as high 
doses (>70.2 Gy) are well tolerated but can lead to mild side-effects like diarrhea and proctitis 
(76). Delayed recovery of sexual function is a possible side-effect of patients treated with 
SRT (77). Acute GU problems tend to recover sooner after the end of RT compared bowel 
symptoms (78). 
 
1.2.5 TECHNIQUE AND DOSING 
 
 The European Association of Urology guidelines recommend doses of 64-66 Gy at a 
PSA of £ 0.5 ng/ml (79). Using the maximum radiation dose with acceptable toxic effects and 
a minimum dose of 64-65 Gy is recommended by the American Society of Radiation Oncolo-
gy (ASTRO) (71). 
 Patients who have a postoperative PSA > 2 ng/ml and a pT3N0 PC are less likely to 
benefit from higher RT doses (80). 
 When performing SRT, irradiating the prostate bed with 70 Gy is recommended to 
accomplish the optimal disease-free survival after RP (81). Doses of 78 Gy delivered to pa-
tients at intermediate-to-high risk increase the freedom from failure but increase the toxic 
effects as well (82). In addition to that, Zietman et al. mention that high doses of 79.2 Gy are 
responsible for a lower risk of biochemical failure in patients with localized PC compared to 
conventional doses of 70.2 Gy (83). On top of that, a longer PSA disease-free survival (PSA-
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DSF) is as well associated with higher radiation doses when the patients were controlled for 
pre-treatment PSA, biopsy GS, and clinical T stage (84). 
 
1.2.6 COMBINATION WITH ANDROGEN DEPRIVATION THERAPY 
 
 A retrospective study was performed on 157 patients treated with RT after receiving 
RP (85). Pre-RT PSA seems to be important for the outcome of SRT. Giving neoadjuvant 
ADT (NADT) to patients with pre-RT PSA of >0.2 ng/ml before SRT, seems to have a bene-
ficial effect on the biochemical disease-free survival (BDFS). In addition to that, they found 
out, that pre-RT PSA <2.0 ng/ml, low GS and positive surgical margins are strong independ-
ent factors for the BDFS prediction. 
 
1.2.7 RESULTS OF TREATMENT 
 
 The prognostic response to SRT can be defined by GS, preradiotherapy PSA level, 
surgical margins, PSADT, and seminal vesicle invasion (73). Progression of PC can be pre-
dicted by GS 8-10, preradiotherapy PSA >2.0 ng/ml, negative surgical margins, PSADT £10 
months, seminal vesicle invasion (73). 
 PSADT is especially important for the prediction of the biochemical control and dis-
ease recurrence because a short PSADT is associated with a worse chance of control (75). 
 The risk of developing metastases can be decreased and the survival can be increased 
by treating the patient with adjuvant radiotherapy (86). Stephenson et al. developed a nomo-
gram in order to predict the cancer control at 6 years for patients who received SRT for recur-
rent PC which was defined by PSA (87). In addition to that, they found out that patients will 
have a long-term PSA response if SRT is started at the first sign of recurrence (87). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. OBJECTIVES 
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 The goal of this single center, retrospective study, was to analyze the outcome [overall 
survival (OS), metastases-free survival (MFS), time to second biochemical progression 
(SBP)] in patients with biochemical relapse after RP receiving SRT, at the Department of 
oncology and Radiotherapy in the University Hospital of Split. Patients treated with SRT 
from the years 2006 until 2015 were included into this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. MATERIALS AND METHODS 
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3.1 DATA COLLECTION: 
 This retrospective cohort study is composed of 124 patients, who were treated with 
salvage RT at the Department of Oncology and Radiotherapy, in the University Hospital of 
Split between the years 2006 and 2015. Values were taken from the individual patients charts 
and missing data was requested from the other institutions in Zadar, Šibenik and Dubrovnik. 
The cut-off for data collection was the 1.2.2018. 
3.2 INVESTIGATED VARIABLES: 
 124 patients treated with SRT were analyzed according to Initial PSA before prosta-
tectomy in ng/ml, PSA after surgery in ng/ml, GS, initial stage, perineal invasion (yes vs. no), 
lymphovascular invasion (yes vs. no), biochemical relapse free survival, median time from 
PSA relapse to start of SRT, PSA at beginning of SRT, PSA response after SRT, dose of radi-
ation, second PSA progression after SRT (yes vs. no), SBP, third biochemical progression 
after ADT, MFS, development of metastases (yes vs. no), and the OS was analyzed and sum-
marized as medians. 
3.3 STATISTICAL ANALYSIS: 
 Statistical analysis was performed by using the MedCalc software for Windows, ver-
sion (MedCalc Software, Mariakerke, Belgium). The Kolmogorov Smirnov test was used to 
assess whether the data was normally distributed or not. 
 Categorical variables were presented using frequencies and percentages and the differ-
ences were tested using Chi squared test, while numerical variables were presented using me-
dian and 95% CI. For survival analysis, the Kaplan Meier analysis was used. The Spearman 
Coefficient was used in order to assess the relationships between the different variables. A 
Correlation was significant with a P<0.05. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS 
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 Table 2 shows the clinical characteristics and outcomes of this study which included 
124 men treated with SRT in the Department of Oncology and Radiotherapy. There was a 
higher PSA level before the surgery compared to the status after surgery (Table 2). 
 
Table 2: clinical characteristics of 124 patients included into this study 
 Median 95% CI 
Age at SRT in years 68 66.6 - 70.0 
Initial PSA level * 9.9 8,6 - 11 
PSA level after surgery * 0,068 0,04 - 0,129 
Biochemical relapse free survival in months 26.00 19.15 - 30.84 
Dose of radiation †  66.0 66.0 - 66.0 
Second biochemical free survival in months 43.50 35,61 - 49.00 
Time from PSA relapse to beginning of SRT in months  5.5 4.0 - 7.0 
Beginning of ADT to progression in months 21 5.81 - 62.11 
Follow-up in months 58.00 50.21 - 67.00 
Metastases-free survival in months 52.50 46.61 – 59.00 
Overall survival in months 53.00 47.00 – 59.39 
Abbreviations: CI, confidence interval; SRT, salvage radiotherapy; PSA, prostate-specific 
antigen; ADT, androgen deprivation therapy 
 * Ng/ml 
† Gray 
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 In Table 3, categorical variables examined in this study are shown. The majority of 
patients presented with a Gleason score of 7. In addition to Gleason score, the TNM stage was 
noted with the majority of patients being staged T2(a-c)N0M0. The presence of lymphovascu-
lar and perineural invasion was mostly not documented in the patient charts. 
 The patients were divided into groups according to the PSA level at the beginning of 
SRT, leading to the majority of patients having a PSA level of less than 0.7 ng/ml. After treat-
ing the patients with SRT, the response to the therapy was measured as percental decrease of 
PSA and grouped according to the amount of decrease. Most of the patients had a high re-
sponse of more than 90%. At the cut-off (1.2.18) of this study, the great majority of patients 
are still alive. 
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Table 3: categorization of the 124 patients included into this study 
Parameter  No. % P value † 
 Gleason score 
 3-6 41 33.1  
 7 63 50.7  
 8-9 17 13.6 <0.001 
unknown 3 2.4  
     
Initial TNM stage 
T1N0M0 8 6.5  
T2(a-c)N0M0 63 50.8  
T3NoMo 34 27.4 <0.001 
T3bN0M0 11 8.9  
 unknown 8 6.5  
     
Perineural invasion yes 30 24.2 <0.001 
 no 27 21.8  
 unknown 67 54  
Lymphovascular invasion yes 47 37.9  
 no 6 4.8 <0.001 
 unknown 71 57.3  
     
 
PSA at beginning of SRT * 
 <0,7 68 54.8  
0,7-1,5 24 19.4  
 1,5-2,0 11 8.9 <0.001 
2,0-4,0 11 8.9  
  >4,0 9 7.3  
 unknown 1 0.8  
PSA response after SRT 
<30% 15 12.1  
30-50% 1 0.8  
50-75% 7 5.6 <0.001 
75-90% 10 8.1  
>90% 80 64.5  
 unknown 11 8.9  
Second PSA progression after SRT yes 33 26.6 <0.001 
no 91 73.4  
   
Third progression (from beginning of ADT to 
progression) 
Valid cases 8 6.45 <0.001 
No progression 116 93.55  
Development of metastases 
yes 4 3.2 <0.001 
no 120 96.8  
  
Survival of patients until 1.2.18 
Alive 112 90.32 <0.001 
Dead  12 9.68  
Abbreviations: GS, Gleason-Score; PSA, prostate-specific antigen; SRT, salvage radiotherapy 
*Ng/ml      † Spearman-Coefficient 
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 In table 4 the correlations between the investigated variables are shown. The lympho-
vascular invasion shows to be related to the MFS (r = -0.21, CI: -0.37 to -0.04, P = 0.015) and 
to OS (r = -0.2484, CI: -0.4069 to -0.07540, P=0.005). Besides lymphovascular invasion, also 
the perineural invasion looks to related to OS (r = -0.19, CI: -0.35 to -0.014, P = 0.034). In 
addition to that, the initial TNM stage shows a relationship to the OS (r = -0.18, 95% Ci = -
0.35 to -0.002, P = 0.047). 
There was no relationship shown between the Initial stage and the metastases-free survival 
(P=0.06. Also, the biochemical relapse free survival shows no relationship to the PSA re-
sponse after therapy (P=0.086), metastases free survival (P=0.269) and the overall survival 
(P=0.119). In addition to that, the Gleason score as well, shows no relationship to the PSA 
response (P=0.066), the MFS (P=0.656) and the OS (P=0.601). Furthermore, there is no sig-
nificant relationship between the PSA response after SRT and the biochemical relapse free 
survival (P=0.086), the MFS (P=0.978) and the OS (P=0.984). 
 The 5-year overall survival of the patients included is 91.7% (95%CI= 85.71 to 97.90) 
(Figure 1); the 5-year biochemical relapse-free survival was 85.51% (95%CI = 76.68 to 
94.33) (figure 2) and the 5-year metastases-free survival was 91.09% (95%CI = 85.00 to 
97.35) (figure 3). 
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TABLE 4: Correlation between evaluated patient characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Correlation (Spearman Coefficient) is significant if below P<0.05 
   Biochemical 
relapse-free 
survival 
Metastases-
free survival 
Overall 
survival 
PSA re-
sponse after 
therapy 
Biochemical relapse 
free survival - 0.269 0.119 0.086 
Lymphovascular 
invasion 0.642 0.015* 0.005* 0.255 
Perineural invasion 0.169 0.071 0.034* 0.064 
Initial TNM stage 0.149 0.063 0.047* 0.149 
Gleason Score 
 0.541 0.656 0.601 0.066 
Dose of radiation 0.769 0.066 0.460 0.894 
PSA response after 
therapy 0.086 0.978 0.985 - 
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Figure 1: Kaplan-Meier survival analysis of the 124 patients included into this study 
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Figure 2: Kaplan-Meier analysis of the biochemical relapse-free survival of the 124 patients 
 
 
Figure 3: Kaplan-Meier analysis of the metastases-free survival of the 124 patients 
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5. DISCUSSION 
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 Prostate cancer is a common problem in men with advancing age. Treating this type of 
cancer is therefore of great interest for the patients as well as the doctors, especially in case of 
failure of primary treatment. In this study we examined those patients who developed a bio-
chemical progression after being treated with RP and for that reason received SRT. Today 
SRT and ADT are the only curative therapies for biochemically recurrent PC with SRT being 
limited to localized PC without metastatic spread. 
 The results of this study show, that patients achieve the best response to SRT when 
therapy is applied early after the biochemical relapse of the disease. Furthermore, a negative 
correlation between the lymphovascular invasion and MFS, OS and between perineural inva-
sion together with the initial TNM and OS was established. 
 We showed, that most of patients who treated after a median time 5,5 month, respond-
ed predominantly with a decrease of the PSA level by more than 90% of the level they had 
before starting SRT. The study made by Choo et al. determined the efficacy of external beam 
radiation as SRT (88). The initial PSA response of 86% to 94% is consistent with the results 
of our study, but then dropped to a complete response of 53% to 62%. The drop in the com-
plete response points to a difference to the response rate determined by us because patients 
treated with SRT did rarely develop an increase of the PSA level after the therapy and there-
fore maintained their results. 
 The PSA level at the beginning of SRT shows to be an important predictor for the re-
sponse to the therapy. Macdonald et al. found out that patients with a PSA < 0.6 ng/ml and 
RT doses of more that 64.8 Gy have the best benefit from SRT (89). These results further 
strengthen the findings of this study, in which we found that patients with a PSA level at the 
beginning of SRT below 0,7 ng/ml achieve good benefits from the therapy. Treating Patients 
with a low PSA level at the beginning of SRT shows an improved response to the therapy 
which is consistent with the results from King (90). 
 As reported by MacDonald et al., treating a biochemically relapsing PC when the PSA 
level is still below 0.5 ng/ml, the biochemical control rate seems to improve (89). The results 
we found, correlate with their findings in the way that less than one third of our patients de-
veloped a second biochemical relapse after introducing SRT and therefore are biochemically 
controlled. 
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 Our findings show that out of 124 patients on 4 developed metastases during the fol-
low-up period. The early application of SRT decreases the development of metastases and 
increases the metastatic-free survival. Studies performed by Stephenson et al. and Boorjian et 
al. show that the application of SRT improves the metastases-free survival and are therefore 
corresponding the before mentioned results (87,91). 
 During the follow-up period of the present study, the five-year survival rate of 91.7% 
was established. The randomized trials by Bolla et al. which shows a survival of 93% and 
Thompson et al. with a survival of approximately 90% in patients staged pT3 (43,86). Fur-
thermore, the Toronto Sunnybrook Regional Cancer Centre came showed survival rates after 
4 years between 89% to 94% (88). These findings confirm the results found by this study. As 
expected, SRT offered to patients having a biochemical relapse after RP at the Department of 
Oncology and Radiotherapy shows similar survival rates as the aforementioned studies. 
 Lymphovascular invasion seems to be negatively related to MFS and OS, meaning 
that no invasion may lead to better survival outcomes in patients treated with SRT. The same 
correlation was established when relating perineural invasion and OS. In addition to that a 
lower initial TNM stage, could possibly have an impact on the OS. Our findings appear to be 
well supported by Stephenson et al. who mentions, that lymphovascular invasion as a predic-
tor of the durable response to SRT (73). In contrast to the beforementioned study in which 
GS, pre SRT PSA level are additional prognostic variables of the response to SRT, we could 
not find a significant relationship between these factors and the MFS and OS. 
 The majority of patients was treated with a median of 66 Gy, resulting decreased PSA 
level of more than 90%. Delivering doses around 66 Gy appears to be related to a good re-
sponse to therapy (89,90). Combining the early start of therapy and the radiation dose, results 
in optimal therapy outcomes and survival. In contrast to these results, we could not establish a 
significant relationship between the administered dose of radiation and the PSA response after 
SRT, MFS and the OS. 
The results produced by this study need to be interpreted with caution. On the one hand, it is 
due to the nonrandomized and retrospective nature of this study. On the other hand, the limi-
tations of our study are due to the missing comparative group which is not treated with SRT 
to calculate the corresponding values for survival. Given the relatively small number of pa-
tients in a single institution, problems in calculating significant differences and relationships 
between the mentioned variables may appear and have to be interpreted with caution.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSION 
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1. The use of SRT in treating patients with a biochemical relapse after RP leads to a good 
response with decreases of PSA levels of more than 90%. 
2. The overall survival is similar to results achieved by other institutions. 
3. The development of metastases can be prevented if therapy is started early and at an 
PSA level lower than 0,7 ng/ml. 
4. If there is less or no involvement of the surrounding tissues in addition to a low initial 
TNM stage, the MFS and OS is improved. 
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Title: Salvage radiotherapy of prostate cancer, retrospective analysis of 10 years’ experience 
in the Department of Oncology and Radiotherapy University Hospital of Split. 
Objectives: We evaluated the clinical outcomes of patients treated with salvage radiotherapy 
(SRT) after biochemical relapse regarding the biochemical control after surgery, overall sur-
vival (OS) and metastatic-free survival (MFS). 
Materials and Methods: A retrospective cohort study (from 2006 until 2015) using the data 
collected from patient charts in the Department of Oncology and Radiotherapy in Split with 
missing data requested from Zadar, Šibenik and Dubrovnik. A total of 124 patients treated 
with salvage radiotherapy after developing biochemical relapse following radical prostatec-
tomy (RP) were included into this study. 
Results: The median follow-up from salvage radiotherapy to the 1.2.18 was 58 months with 
68 years being the median age of the patients. Therapy was started after a median of 5.5 
months. Out of the 124 patients, 68 started SRT with a PSA level below 0.7 ng/ml. 80 patients 
responded to the therapy with drop in PSA of more than 90%. Progression after SRT was ob-
served in 33 patients and 4 patients developed metastases. This leads to a median biochemical 
relapse-free survival (BRFS) of 26 months, OS of 53 months, an MFS of 52.5 months. The 5-
year overall survival of the patients included is 91.7% (95%CI= 85.71 to 97.90); the 5-year 
biochemical relapse-free survival was 85.51% (95%CI = 76.68 to 94.33) and the 5-year me-
tastases-free survival was 91.09% (95%CI = 85.00 to 97.35). A relationship was shown be-
tween lymphovascular invasion and MFS (P=0.015) and OS (P=0.005). Perineural invasion 
(P=0.034) and the TNM stage (P=0.047) show a relation to OS. Other relationships were not 
observed. 
Conclusion: Patients treated with SRT show a good biochemical response after the therapy. If 
the surrounding tissues were not involved and the initial TNM stage is low, the outcomes im-
prove leading to a better MFS and OS. 
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Naslov: "Salvage"-radioterapija (SRT) karcinoma prostate, retrospektivna analiza 
desetgodišnjeg iskustva Klinike za onkologiju i radioterapiju Kliničkog bolničkog centra 
Split. 
 
Ciljevi: Evaluacija ishoda liječenja pacijenata SRT kod biokemijskog recidiva nakon 
radikalne prostatektomije obzirom na biokemijsku kontrolu (PSA), ukupno preživljavanje 
(OS) i preživljavanje bez metastaza (MFS). 
 
Materijali i metode: Retrospektivna kohortna studija (od 2006 do 2015) na osnovu podataka 
dobivenih iz povijesti bolesti pacijenata s Klinike za onkologiju i radioterapiju u Splitu, te s 
odjela onkologije OB bolnica u Zadru, Šibeniku i Dubrovniku. Ukupno je u studiji obrađeno 
124 pacijenta koji su liječeni SRT zbog biokemijskog recidiva nakon radikalne 
prostatektomije. 
 
Rezultati: Medijan praćenja nakon SRT je bio 58 mjeseci (do 01.02.2018), medijan dobi 
pacijenata iznosi 68 godina. Sa SRT se počelo u prosijeku nakon 5,5 mjeseci. Kod 68 
pacijenata od ukupno 124, počelo se sa SRT kod vrijednosti PSA ispod 0,7 ng/ml. Kod 80 
pacijenata je pala vrijednost PSA za više od 90%. Biokemijska progresija bolesti nakon SRT 
je primjećena kod 33 pacijenata, a u 4 pacijenta su se razvile presadnice. To odgovara 
medijanu preživljenja bez biokemijskog recidiva (bRFS) od 26 mjeseci, medijanu ukupnog 
preživljenja (OS) od 53 mjeseca i medijanu preživljenja bez metastaza (MFS) od 52,5 
mjeseci. Stopa petogodišnjeg preživljenja iznosi 91,7% (95%CI= 85.71 do 97.90); 
petogodišnje preživljenje bez biokemijskog recidiva iznosi 85.51% (95%CI = 76.68 do 94.33) 
i petogodišnje preživljenje bez metastaza iznosi 91.09% (95%CI = 85.00 to 97.35). Postoji 
povezanost između limfovaskularne invazije i preživljavanja bez metastasa (MFS) (P=0,015) 
i ukupnog preživljavanja (OS) (P=0,005). Nadalje postoji povezanost perineuralne invazije 
(P=0,034) i TNM-stadija (P=0,047) s ukupnim preživljavanjem. 
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Zaključci: Salvage-radioterapija kod pacijenata s biokemijskim rezidivom nakon radikalne 
prostatektomije uzrokuje pad vrijednosti PSA PSA i utječe na ukupno preživljenje, 
preživljenje bez biokemijske progresije i preživljenje bez pojave presadnica Izostanak 
tumorske infiltracije okolnog tkiva i niski inicijalni TNM-stadij poboljšavaju prognozu 
obzirom na preživljavanje bez metastaza (MFS) i ukupno preživljavanje (OS). 
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